EMAS Pharma Rebrands as Evestia Clinical

Evestia Clinical - the new brand identity for EMAS Pharma - launches  as a market leading pharmaceutical research  specialist focussed on Clinical Trials in Oncology and Rare  Diseases.

Letchworth Garden City, 20th March 2025 – Evestia Clinical has today been  announced as the new identity of EMAS Pharma, as it sets its sights on rapid growth as a  provider of clinical research in oncology and rare diseases globally. 

Evestia Clinical is backed by Kester Capital and headed by a strong leadership team  including Richard Barfield (Chairman), Lewis Cameron (CEO), Roy Ovel (CCO), and Carl  Hvass (CFO). The name Evestia is inspired by the company’s mission to pioneer  transformational advancements in clinical research. It represents a commitment to making  a lasting imprint in the industry by driving meaningful progress in oncology and rare  disease trials and strengthening partnerships with biotech companies.

 “The launch of Evestia Clinical marks an exciting new chapter in our journey,” said Richard  Barfield, Chairman of Evestia Clinical.  

“Our leadership team has a proven track record of driving growth in the CRO sector, and  with the support of Kester Capital, we are well-positioned to accelerate our expansion,  strengthen our service offerings, and broaden our global reach. We are building a worldclass platform that will deliver exceptional value to our biotech clients. 

“Our new identity reaffirms our focus on delivering high-quality clinical trials in oncology  and rare diseases, where there is an urgent need for innovation and speed. We are firmly  placed to support biotech companies in bringing life-changing therapies to market.” 

Evestia Clinical’s mission is clear: To empower biotech innovators by providing expertdriven, agile, and personalized clinical research solutions - accelerating the development  of life-changing therapies with confidence and care. This mission reflects its unwavering  commitment to excellence, integrity, and innovation in the pursuit of advancing healthcare  worldwide.

“We are committed to providing our clients with the most effective and adaptive clinical  trial solutions,” said Lewis Cameron, CEO. “This transformation aligns with our long-term  vision of being the preferred CRO partner for biotech companies focused on complex, highimpact research areas.” 

Adam Maidment, Managing Partner at Kester Capital, commented: “Kester has been investing in CROs

for over a decade, and we see Evestia Clinical as a highly strategic platform in a dynamic and fast-growing global market. We are delighted to be partnering  once again with Richard, Lewis, Roy, Carl, and the existing Evestia Clinical team to support  the next phase of growth - both organically and through acquisition as they continue to  drive innovation in clinical research.” 

About Evestia Clinical 

Evestia Clinical is a leading CRO specializing in clinical trials for oncology and rare diseases.  With a commitment to scientific excellence, innovation, and patient-centric research,  Evestia Clinical partners with biotech companies to accelerate the development of lifesaving therapies. Backed by Kester Capital, Evestia Clinical is dedicated to advancing  healthcare through cutting-edge clinical research. Evestia Clinical’s vision is to be the market-leading clinical service partner for biotechs and  beyond - fuelling medical breakthroughs to improve global health within a culture that  values, inspires, and empowers.